Application of TLR9 agonists for asthma/allergy

In May 2005, Idera entered into a research collaboration and option agreement and a separate license, development and commercialization agreement with Novartis to discover, develop and potentially commercialize TLR9 agonists that are identified as potential treatments for asthma and allergies.

In September 2008, Idera announced that Novartis initiated a Phase 1 clinical study of QAX935, also known as IMO-2134, a novel TLR9 agonist identified under the research collaboration.

Novartis scientists gave a presentation of preclinical data entitled “Effects of a novel synthetic TLR9 agonist on repeated allergen challenge in allergic monkeys” during the TOLL2008 meeting held in Cascais, Portugal. Idera has received notification from Novartis that Novartis has terminated the research collaboration and option agreement effective as of February 21, 2010. [Press Release]

Please click here for more information on this collaboration